Quantification of IgG antibodies against SARS-CoV-2 on the staff of the Rawson Hospital, Córdoba Province, Argentina

Abstract

Introduction: The quantitative assay called IgG II against SARS-CoV-2 has been available on the market since December 2020, and the nationwide vaccination of the population with Sputnik V began on December 29, 2020. Aim: To quantify the IgG anti-SARS-CoV-2 antibodies produced in women and men in response to vaccination with Sputnik V, and to evaluate whether they differ between patients who had the infection and those who did not and whether they differ between sexes. Materials and Methods: Postvaccination samples of the staff of the Rawson Hospital, Córdoba Province, Argentina, were collected 14, 42, and 60 days after the first dose of the Sputnik V vaccine. Samples were classified by sex and based on SARS-CoV-2 infections or not. The antibodies were quantified with the SARS-CoV-2 IgG Quant kit. The data were statistically analyzed with the software InfoStat using the Mann-Whitney test. The level of significance was 5%. Results: Sex would not be a differentiating factor in the concentration of antibodies in patients without previous infection (p>0.05) on days 14, 42, and 60 post-vaccination. Patients who had suffered the infectionshowed no significant differences on days 14 and 60 post-vaccination (p>0.05), but on days 42 post-vaccination (p<0.05). Conclusion: Different reports have concluded that a dose of vaccination in people previously infected with SARS-CoV-2 results in a significant increase in the concentration of antibodies and, thus, the second dose could be postponed. This would justify the vaccination with two doses for the people who did not suffer from the disease.